• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

与前列腺体积相关的良性前列腺增生基因表达谱。

BPH gene expression profile associated to prostate gland volume.

作者信息

Descazeaud Aurelien, Rubin Mark A, Hofer Matthias, Setlur Sunita, Nikolaief Nathalie, Vacherot Francis, Soyeux Pascale, Kheuang Laurence, Abbou Claude C, Allory Yves, de la Taille Alexandre

机构信息

INSERM, Unité 841, IMRB, Faculté de Médecine, University Paris 12, France.

出版信息

Diagn Mol Pathol. 2008 Dec;17(4):207-13. doi: 10.1097/PDM.0b013e31816f6352.

DOI:10.1097/PDM.0b013e31816f6352
PMID:18936709
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2822796/
Abstract

The aim of the current study was to analyze gene expression profiles in benign prostatic hyperplasia and to compare them with phenotypic properties. Thirty-seven specimens of benign prostatic hyperplasia were obtained from symptomatic patients undergoing surgery. RNA was extracted and hybridized to Affymetrix Chips containing 54,000 gene expression probes. Gene expression profiles were analyzed using cluster, TreeView, and significance analysis of microarrays softwares. In an initial unsupervised analysis, our 37 samples clustered hierarchically in 2 groups of 18 and 19 samples, respectively. Five clinical parameters were statistically different between the 2 groups: in group 1 compared with group 2, patients had larger prostate glands, had higher prostate specific antigen levels, were more likely to be treated by alpha blockers, to be operated by prostatectomy, and to have major irritative symptoms. The sole independent parameter associated with this dichotome clustering, however, was the prostate gland volume. Therefore, the role of prostate volume was explored in a supervised analysis. Gene expression of prostate glands <60 mL and >60 mL were compared using significance analysis of microarrays and 227 genes were found differentially expressed between the 2 groups (>2 change and false discovery rate of <5%). Several specific pathways including growth factors genes, cell cycle genes, apoptose genes, inflammation genes, and androgen regulated genes, displayed major differences between small and large prostate glands.

摘要

本研究的目的是分析良性前列腺增生中的基因表达谱,并将其与表型特征进行比较。从接受手术的有症状患者中获取了37份良性前列腺增生标本。提取RNA并与含有54000个基因表达探针的Affymetrix芯片杂交。使用聚类、TreeView和微阵列软件的显著性分析来分析基因表达谱。在最初的无监督分析中,我们的37个样本分别分层聚为18个样本和19个样本的两组。两组之间有五个临床参数在统计学上存在差异:与第2组相比,第1组患者的前列腺更大,前列腺特异性抗原水平更高,更有可能接受α受体阻滞剂治疗、接受前列腺切除术,并且有更严重的刺激性症状。然而,与这种二分聚类相关的唯一独立参数是前列腺体积。因此,在有监督分析中探讨了前列腺体积的作用。使用微阵列显著性分析比较了前列腺体积<60 mL和>60 mL的基因表达,发现两组之间有227个基因差异表达(变化>2倍且错误发现率<5%)。包括生长因子基因、细胞周期基因、凋亡基因、炎症基因和雄激素调节基因在内的几个特定途径,在小前列腺和大前列腺之间显示出主要差异。

相似文献

1
BPH gene expression profile associated to prostate gland volume.与前列腺体积相关的良性前列腺增生基因表达谱。
Diagn Mol Pathol. 2008 Dec;17(4):207-13. doi: 10.1097/PDM.0b013e31816f6352.
2
Distinctive gene expression of prostatic stromal cells cultured from diseased versus normal tissues.从患病组织与正常组织培养的前列腺基质细胞的独特基因表达。
J Cell Physiol. 2007 Jan;210(1):111-21. doi: 10.1002/jcp.20828.
3
Bipolar plasma enucleation of the prostate vs open prostatectomy in large benign prostatic hyperplasia cases - a medium term, prospective, randomized comparison.经尿道双极等离子前列腺剜除术与开放性前列腺切除术治疗大体积良性前列腺增生症的中期前瞻性随机对照研究。
BJU Int. 2013 May;111(5):793-803. doi: 10.1111/j.1464-410X.2012.11730.x. Epub 2013 Mar 7.
4
A retrospective study: correlation of histologic inflammation in biopsy specimens of Chinese men undergoing surgery for benign prostatic hyperplasia with serum prostate-specific antigen.一项回顾性研究:在中国男性接受良性前列腺增生手术的活检标本中,组织学炎症与血清前列腺特异性抗原的相关性。
Urology. 2011 Mar;77(3):688-92. doi: 10.1016/j.urology.2010.07.493. Epub 2010 Oct 25.
5
Gene expression signature of benign prostatic hyperplasia revealed by cDNA microarray analysis.通过cDNA微阵列分析揭示的良性前列腺增生的基因表达特征。
Prostate. 2002 May 15;51(3):189-200. doi: 10.1002/pros.10087.
6
Mid term outcomes of initial 250 case experience with GreenLight 120W-HPS photoselective vaporization prostatectomy for benign prostatic hyperplasia: comparison of prostate volumes < 60 cc, 60 cc-100 cc and > 100 cc.采用绿激光120W高功率选择性汽化术治疗良性前列腺增生症的首批250例病例的中期结果:前列腺体积<60立方厘米、60立方厘米-100立方厘米和>100立方厘米的比较
Can J Urol. 2012 Oct;19(5):6450-8.
7
Prognostic role of prostate-specific antigen and prostate volume for the risk of invasive therapy in patients with benign prostatic hyperplasia initially managed with alpha1-blockers and watchful waiting.前列腺特异性抗原和前列腺体积对最初采用α1受体阻滞剂治疗并密切观察等待的良性前列腺增生患者进行侵入性治疗风险的预后作用。
Urology. 2005 Feb;65(2):300-5. doi: 10.1016/j.urology.2004.09.030.
8
Molecular genetic profiling of Gleason grade 4/5 prostate cancers compared to benign prostatic hyperplasia.与良性前列腺增生相比, Gleason 4/5级前列腺癌的分子遗传特征分析
J Urol. 2001 Dec;166(6):2171-7.
9
Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling.人类前列腺癌和良性前列腺增生:通过基因表达谱进行分子剖析。
Cancer Res. 2001 Jun 15;61(12):4683-8.
10
Transforming growth factor β-receptor II protein expression in benign prostatic hyperplasia is associated with prostate volume and inflammation.转化生长因子 β 受体 II 蛋白在良性前列腺增生中的表达与前列腺体积和炎症有关。
BJU Int. 2011 Jul;108(2 Pt 2):E23-8. doi: 10.1111/j.1464-410X.2010.09699.x. Epub 2010 Sep 14.

引用本文的文献

1
IL-27/IL-27RA signaling may modulate inflammation and progression of benign prostatic hyperplasia via suppressing the LPS/TLR4 pathway.白细胞介素-27/白细胞介素-27受体信号通路可能通过抑制脂多糖/ Toll样受体4途径来调节良性前列腺增生的炎症反应和进展。
Transl Cancer Res. 2020 Aug;9(8):4618-4634. doi: 10.21037/tcr-20-1509.
2
Unraveling the dark matter, long non-coding RNAs, in male reproductive diseases: A narrative review.解析男性生殖疾病中的“暗物质”——长链非编码RNA:一篇综述
Int J Reprod Biomed. 2020 Nov 22;18(11):921-934. doi: 10.18502/ijrm.v13i11.7959. eCollection 2020 Nov.
3
Integrative multiplatform molecular profiling of benign prostatic hyperplasia identifies distinct subtypes.

本文引用的文献

1
A novel splicing variant of proprotein convertase subtilisin/kexin type 9.前蛋白转化酶枯草杆菌蛋白酶/九型凯新的一种新型剪接变体。
DNA Cell Biol. 2008 Apr;27(4):183-9. doi: 10.1089/dna.2007.0667.
2
Functional analysis of the host defense peptide Human Beta Defensin-1: new insight into its potential role in cancer.宿主防御肽人β-防御素-1的功能分析:对其在癌症中潜在作用的新见解。
Mol Immunol. 2008 Feb;45(3):839-48. doi: 10.1016/j.molimm.2006.11.026. Epub 2007 Sep 14.
3
Distribution of 15 human kallikreins in tissues and biological fluids.
良性前列腺增生的综合多平台分子特征分析可确定不同亚型。
Nat Commun. 2020 Apr 24;11(1):1987. doi: 10.1038/s41467-020-15913-6.
4
Transforming growth factor beta 1 impairs benign prostatic luminal epithelial cell monolayer barrier function.转化生长因子β1损害良性前列腺管腔上皮细胞单层屏障功能。
Am J Clin Exp Urol. 2020 Feb 25;8(1):9-17. eCollection 2020.
5
Targeting phenotypic heterogeneity in benign prostatic hyperplasia.针对良性前列腺增生中的表型异质性。
Differentiation. 2017 Jul-Aug;96:49-61. doi: 10.1016/j.diff.2017.07.005. Epub 2017 Aug 4.
6
The many ways to make a luminal cell and a prostate cancer cell.制造管腔细胞和前列腺癌细胞的多种方法。
Endocr Relat Cancer. 2015 Dec;22(6):T187-97. doi: 10.1530/ERC-15-0195. Epub 2015 Aug 25.
7
Biological effect of human serum collected before and after oral intake of Pygeum africanum on various benign prostate cell cultures.口服非洲臀果木提取物前后的人血清对各种良性前列腺细胞培养物的生物学效应。
Asian J Androl. 2012 May;14(3):499-504. doi: 10.1038/aja.2011.132. Epub 2011 Dec 26.
8
Silodosin in the treatment of benign prostatic hyperplasia.西洛多辛治疗良性前列腺增生症。
Drug Des Devel Ther. 2010 Oct 27;4:291-7. doi: 10.2147/DDDT.S10428.
9
Inhibition of inflammatory gene expression in keratinocytes using a composition containing carnitine, thioctic Acid and saw palmetto extract.使用包含肉碱、硫辛酸和锯棕榈提取物的组合物抑制角质形成细胞中炎症基因的表达。
Evid Based Complement Alternat Med. 2011;2011:985345. doi: 10.1093/ecam/nep102. Epub 2011 Jun 8.
10
Lower urinary tract symptoms, benign prostatic hyperplasia, and obesity.下尿路症状、良性前列腺增生与肥胖
Curr Urol Rep. 2009 Jul;10(4):247-53. doi: 10.1007/s11934-009-0041-8.
15种人组织激肽释放酶在组织和生物体液中的分布
Clin Chem. 2007 Aug;53(8):1423-32. doi: 10.1373/clinchem.2007.088104. Epub 2007 Jun 15.
4
Identification of novel androgen receptor target genes in prostate cancer.前列腺癌中新型雄激素受体靶基因的鉴定
Mol Cancer. 2007 Jun 6;6:39. doi: 10.1186/1476-4598-6-39.
5
Is benign prostatic hyperplasia (BPH) an immune inflammatory disease?良性前列腺增生(BPH)是一种免疫炎症性疾病吗?
Eur Urol. 2007 May;51(5):1202-16. doi: 10.1016/j.eururo.2006.12.011. Epub 2006 Dec 11.
6
Tyrosine kinase inhibitor CEP-701 blocks the NTRK1/NGF receptor and limits the invasive capability of prostate cancer cells in vitro.酪氨酸激酶抑制剂CEP-701可阻断NTRK1/NGF受体,并在体外限制前列腺癌细胞的侵袭能力。
Int J Oncol. 2007 Jan;30(1):193-200.
7
Long-Term Experience With 5-alpha-Reductase Inhibitors.5α-还原酶抑制剂的长期使用经验
Rev Urol. 2003;5 Suppl 5(Suppl 5):S22-7.
8
5-alpha-Reductase Inhibitors Prevent the Progression of Benign Prostatic Hyperplasia.5α-还原酶抑制剂可预防良性前列腺增生的进展。
Rev Urol. 2003;5 Suppl 5(Suppl 5):S12-21.
9
Benign prostatic hyperplasia: does prostate size matter?良性前列腺增生:前列腺大小重要吗?
Rev Urol. 2003;5 Suppl 4(Suppl 4):S12-7.
10
Expression analysis of peptide growth factors VEGF, FGF2, TGFB1, EGF and IGF1 in prostate cancer and benign prostatic hyperplasia.肽生长因子VEGF、FGF2、TGFB1、EGF和IGF1在前列腺癌和良性前列腺增生中的表达分析。
Int J Oncol. 2006 Aug;29(2):305-14.